This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Avalon GloboCare’s 8K filing here.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.
Featured Articles
- Five stocks we like better than Avalon GloboCare
- 3 Warren Buffett Stocks to Buy Now
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
- There Are Different Types of Stock To Invest In
- 3 Stocks With Rising Prices That Are Likely to Split in 2025
- What is Put Option Volume?
- Why Adobe Stock Could Be the Best Dip Buy in Tech Right Now
